QT-019C clinical trials
Also written QT-019C.
How each study uses QT-019C is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the QT-019C studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- QT-019C
- 3
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 3
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) · Tianjin Huanhu Hospital (1) · Institute of Hematology & Blood Diseases Hospital, China (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test QT-019C.
- Jun 2027Universal Chimeric Antigen Receptor T-Cell (UCAR T-cell) Therapy Targeting CD19/ BCMA(QT-019C) in Patients With r/ r Neurological Autoimmune DiseasesEarly Phase 1 · Tianjin Huanhu Hospital
Studies
Open first, then newest update. How each study uses QT-019C is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C)in Patients With Refractory Primary Immune ThrombocytopeniaNot yet recruitingEarly Phase 1Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNCT07416032Written as QT-019CHow we know
- Universal Chimeric Antigen Receptor T-Cell (UCAR T-cell) Therapy Targeting CD19/ BCMA(QT-019C) in Patients With r/ r Neurological Autoimmune DiseasesNot yet recruitingEarly Phase 1Tianjin Huanhu HospitalNCT07392528Written as QT-019CHow we know
- CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune DiseasesRecruitingPhase 1Institute of Hematology & Blood Diseases Hospital, ChinaNCT07315087Written as QT-019CHow we know